Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hi-Xenin refers to a high-dose intravenous infusion of the peptide hormone xenin, typically at 12 pmol·kg⁻¹·min⁻¹, used in clinical research settings. Xenin is a 25-amino acid peptide (xenin-25) related to neurotensin and secreted by enteroendocrine K-cells in the gastrointestinal tract. In human studies, "Hi-Xen" infusions have been shown to delay gastric emptying and reduce postprandial glucose levels in individuals with normal glucose tolerance (NGT), impaired glucose tolerance (IGT), and type 2 diabetes mellitus (T2DM). The mechanism involves modulation of gastrointestinal motility and appetite regulation via central and peripheral pathways. Xenin also exhibits anorexigenic effects—reducing calorie intake—and may augment insulin secretion or restore GIP sensitivity, making it an attractive candidate for metabolic disease research[2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Hi-Xenin.